Solventum beat Wall Street in Q1 with $2.1B in sales (up 2.6%) and adjusted EPS of $1.34—12¢ above consensus. The former 3M health unit also raised its 2025 organic sales growth forecast to 1.5–2.5%.
Shares jumped 5% as CEO Bryan Hanson emphasized a focus on transformation and strategic execution, despite tariff-related profitability headwinds of up to $100M. The company remains on track with its $120M cost-saving plan following recent layoffs.
All four business segments showed solid performance.
Follow MEDWIRE.AI for earnings updates on MedTech spinoffs and restructuring news.
